projects:workgroups:clinicalstudy
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
projects:workgroups:clinicalstudy [2024/08/19 14:08] mikehamidi |
projects:workgroups:clinicalstudy [2025/05/11 15:58] (current) mikehamidi |
||
|---|---|---|---|
| Line 10: | Line 10: | ||
| **Status**:\\ | **Status**:\\ | ||
| + | - 2025: CTWG is providing new chapter content (Clinical Trial Data) for the upcoming Book of OHDSI update. | ||
| - 2024: The finalization of C-Path SDTM-to-OMOP mappings is underway, with an emphasis on matching concept codes using Usagi. The next step is to execute ETL queries to generate the OMOP CDM tables. Additionally, a secondary objective is to identify general conventions and best practices for clinical trials. These conventions will be applied to additional C-Path SDTM study data to uncover any further gaps or challenges. \\ | - 2024: The finalization of C-Path SDTM-to-OMOP mappings is underway, with an emphasis on matching concept codes using Usagi. The next step is to execute ETL queries to generate the OMOP CDM tables. Additionally, a secondary objective is to identify general conventions and best practices for clinical trials. These conventions will be applied to additional C-Path SDTM study data to uncover any further gaps or challenges. \\ | ||
| - 2023: The team has transitioned from using Vivli (due to access constraints) data to leveraging SDTM data provided by C-Path for tuberculosis. The development of mapping specifications for the subsequent ETL process will proceed from the initial stages.\\ | - 2023: The team has transitioned from using Vivli (due to access constraints) data to leveraging SDTM data provided by C-Path for tuberculosis. The development of mapping specifications for the subsequent ETL process will proceed from the initial stages.\\ | ||
| Line 44: | Line 45: | ||
| **WG co-leads**: | **WG co-leads**: | ||
| - | Mike Hamidi | + | Open Spot |
| and | and | ||
| Kenneth Wilkins | Kenneth Wilkins | ||
| + | **WG past leads**: | ||
| + | Mike Hamidi, Tom Walpole, Zhen Li, Sonia Araujo | ||
| **Active members**\\ | **Active members**\\ | ||
| Line 57: | Line 60: | ||
| | Melissa Cook | Essex Management | Boston, MA, USA | [[http://www.linkedin.com/in/mkcook|{{:wiki:linkedinicon.png?20}}]] | | | Melissa Cook | Essex Management | Boston, MA, USA | [[http://www.linkedin.com/in/mkcook|{{:wiki:linkedinicon.png?20}}]] | | ||
| | Diane Corey | Critical Path Institute | Tucson, AZ, USA | | | | Diane Corey | Critical Path Institute | Tucson, AZ, USA | | | ||
| - | | Shital Desai | | USA | | | + | | Shital Desai | Independent | USA | | |
| - | | Kerry Goetz | National Institute of Health; \\ National Eye Institute | Bethesda, MD, USA | [[https://www.linkedin.com/in/kerrygoetz/|{{:wiki:linkedinicon.png?20}}]] | | + | | Kerry Goetz | National Institute of Health; \\ National Eye Institute | Bethesda, MD, USA | [[https://www.linkedin.com/in/kerrygoetz/|{{:wiki:linkedinicon.png?20}}]] |
| - | | Priya Gopal | Flatiron Health | New York, NY, USA | | | + | | Mike Hamidi | Walmart Healthcare Research Institute | USA | [[https://www.linkedin.com/in/kamiar-mike-hamidi-0a908164/|{{:wiki:linkedinicon.png?20}}]] | |
| - | | Mike Hamidi | DataInterop LLC | New Jersey, USA | [[https://www.linkedin.com/in/kamiar-mike-hamidi-0a908164/|{{:wiki:linkedinicon.png?20}}]] | | + | | Dan Hartley | Critical Path Institute | USA | | |
| - | | Dan Hartley | | USA | | | + | |
| | Ying Huang |National Institute of Health | USA | | | | Ying Huang |National Institute of Health | USA | | | ||
| | Asiyah Yu Lin | National Institute of Health | Bethesda, MD, USA | | | Asiyah Yu Lin | National Institute of Health | Bethesda, MD, USA | | ||
| Line 68: | Line 70: | ||
| | Terrence McHugh | Critical Path Institute | Tucson, AZ, USA | | | | Terrence McHugh | Critical Path Institute | Tucson, AZ, USA | | | ||
| | Priya Meghrajani | Talosix | Seattle, WA, USA | | | | Priya Meghrajani | Talosix | Seattle, WA, USA | | | ||
| - | | Pam Nesbitt | | USA | | | ||
| | Paul Orona | | USA | | | | Paul Orona | | USA | | | ||
| | Daniel Olson | Critical Path Institute | Tucson, AZ, USA | | | | Daniel Olson | Critical Path Institute | Tucson, AZ, USA | | | ||
projects/workgroups/clinicalstudy.1724076503.txt.gz · Last modified: 2024/08/19 14:08 by mikehamidi
Page Tools
